Chronic progressive external ophthalmoplegia

From WikiMD's Medical Encyclopedia

Revision as of 19:43, 26 March 2025 by Prab (talk | contribs)

A mitochondrial disorder affecting eye muscles


Chronic progressive external ophthalmoplegia
Synonyms Progressive external ophthalmoplegia, CPEO
Pronounce /ˈɒfθəlmoʊˌpliːdʒə/
Specialty N/A
Symptoms Gradual paralysis of the extraocular muscles, ptosis, limited eye movement, muscle weakness, exercise intolerance
Complications Dysphagia, cardiomyopathy, sensorineural hearing loss, diabetes mellitus
Onset Typically in young adulthood or middle age
Duration Chronic and progressive
Types CPEO, CPEO plus (includes systemic symptoms)
Causes Mutations in mitochondrial DNA (mtDNA) or nuclear DNA, such as POLG, TWNK, RRM2B
Risks Family history of mitochondrial disease, genetic mutations
Diagnosis Muscle biopsy, genetic testing, EMG, MRI, ophthalmological exam
Differential diagnosis Myasthenia gravis, Graves' ophthalmopathy, Kearns–Sayre syndrome, oculopharyngeal muscular dystrophy
Prevention None known; genetic counseling may be helpful
Treatment Supportive care, eyelid surgery, eye protection, physical therapy, aids for ptosis
Medication No disease-specific drugs; coenzyme Q10 and vitamins may be used supportively
Prognosis Slowly progressive; often compatible with normal life expectancy
Frequency Rare; exact incidence unknown
Deaths Not typically fatal; related systemic complications may affect prognosis


Chronic progressive external ophthalmoplegia (CPEO) is a rare neuromuscular disorder characterized by slowly progressive paralysis of the extraocular muscles, which are responsible for controlling eye movements. This condition leads to ptosis (drooping of the eyelids) and limited eye movement, often resulting in diplopia (double vision). CPEO is primarily associated with mitochondrial myopathy, a type of mitochondrial disease.

Pathophysiology

CPEO is caused by defects in the mitochondria, the energy-producing structures within cells. These defects can result from mutations in nuclear DNA or mitochondrial DNA (mtDNA). The mutations lead to impaired energy production, particularly affecting tissues with high energy demands, such as the muscles controlling eye movement. The accumulation of dysfunctional mitochondria in these muscles results in their progressive weakness and paralysis.

Clinical Features

The hallmark of CPEO is the gradual onset of ophthalmoplegia, which typically begins in adulthood. Patients often present with:

  • Ptosis: Drooping of one or both eyelids, which may be the initial symptom.
  • Ophthalmoplegia: Limited movement of the eyes in all directions, leading to difficulty in tracking objects and diplopia.
  • Facial Weakness: Some patients may experience mild weakness of the facial muscles.
  • Muscle Weakness: In some cases, CPEO may be associated with generalized muscle weakness, particularly in the limbs.

Diagnosis

The diagnosis of CPEO is based on clinical examination, family history, and specialized tests. Key diagnostic tools include:

  • Ophthalmologic Examination: To assess the extent of eye movement limitation and ptosis.
  • Muscle Biopsy: May reveal characteristic "ragged-red fibers," indicative of mitochondrial myopathy.
  • Genetic Testing: To identify mutations in mtDNA or nuclear DNA associated with CPEO.
  • Electromyography (EMG): To evaluate muscle function and detect abnormalities.

Management

There is currently no cure for CPEO, and treatment is primarily supportive. Management strategies include:

  • Ptosis Surgery: To improve eyelid function and vision.
  • Prism Glasses: To alleviate diplopia by correcting eye alignment.
  • Physical Therapy: To maintain muscle strength and function.
  • Genetic Counseling: For affected individuals and their families to understand the inheritance patterns and risks.

Prognosis

CPEO is a progressive condition, but the rate of progression can vary widely among individuals. While the disorder primarily affects eye muscles, some patients may develop additional symptoms related to mitochondrial dysfunction, such as cardiac conduction defects or sensorineural hearing loss.

Related Pages



This article is a medical stub. You can help WikiMD by expanding it!
PubMed
Wikipedia
Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?

Get started with evidence based, physician-supervised

affordable GLP-1 weight loss injections

Now available in New York City and Philadelphia:

✔ Evidence-based medical weight loss ✔ Insurance-friendly visits available ✔ Same-week appointments, evenings & weekends

Learn more:

Start your transformation today with W8MD weight loss centers.

Advertise on WikiMD


WikiMD Medical Encyclopedia

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.